美国医疗保健系统中特定适应症的药品定价。
Indication-specific pricing of pharmaceuticals in the US healthcare system.
作者信息
Pearson Steven D, Dreitlein William B, Henshall Chris, Towse Adrian
机构信息
Institute for Clinical & Economic Review, Two Liberty Square, 9th Floor, Boston, MA 02109, USA.
Brunel University London, Kingston Ln, London, Uxbridge UB8 3PH, UK.
出版信息
J Comp Eff Res. 2017 Jul;6(5):397-404. doi: 10.2217/cer-2017-0018. Epub 2017 Jul 12.
AIM
To explore the potential of indication-specific pricing (ISP) of pharmaceuticals and to discuss prospects for implementation in the US healthcare system.
MATERIALS & METHODS: The Institute for Clinical and Economic Review convened a policy forum with 44 healthcare leaders from 22 payer and life sciences companies. Models of ISP were discussed.
RESULTS
Payers and drug manufacturers saw the potential benefits of an ISP system that balances affordability for payers, sustainability for manufacturers and access for patients. The US healthcare system presents many challenges to implementation, including potential conflicts with existing pricing policies (Medicaid Best Price, average sales price and 340B) and insufficient data systems and analytic capabilities.
CONCLUSION
Possible solutions and policy recommendations for payers and manufacturers are provided.
目的
探讨药品特定适应症定价（ISP）的潜力，并讨论其在美国医疗保健系统中的实施前景。
材料与方法
临床与经济评论研究所召集了一次政策论坛，与会者包括来自22家支付方和生命科学公司的44位医疗保健领域领导者。会上讨论了ISP模式。
结果
支付方和药品制造商看到了ISP系统的潜在益处，该系统能平衡支付方的可承受性、制造商的可持续性以及患者的可及性。美国医疗保健系统在实施方面面临诸多挑战，包括与现有定价政策（医疗补助最佳价格、平均销售价格和340B）的潜在冲突，以及数据系统和分析能力不足。
结论
为支付方和制造商提供了可能的解决方案和政策建议。
Zotero 插件